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We compared the ability of four newer (l-lactam compounds to produce resistance in an
experimental model of Enterobacter cloacae infection. Mice infected intraperitoneally
developed resistance depending on antibiotic treatment and the dose given. Percentages
of mice in which resistancewasobservedwere as follows: 100% after ceftriaxone (50mg/kg,
two doses); 87% after ceftriaxone (50mg/kg, one dose); 35070 after ceftriaxone (500mg/kg,
one dose); and 21% after carumonam (25 mg/kg, two doses). No resistance occurred af-
ter therapy with either BMY 28142(25 mg/kg, two doses) or Sch 34343 (50 mg/kg, two
doses). Heterogeneous resistance to 13-lactams among the cells within a given Enterobac-
ter population accounted for these differences. The minimal concentration inhibiting the
growth of the preexisting resistant variants, together with the antibiotic concentrations
obtained in the peritoneal fluid, wereassociated with further emergence of resistance in
the mouse treated with this antibiotic.
Some gram-negative bacteria, although classified as
susceptible with the conventional susceptibility test-
ings, become resistant during therapy with newer 13-
lactam compounds. Bacterial species possessing this
capacity include mainly Pseudomonas aeruginosa,
Enterobacter cloacae, Serratia marcescens, and
Citrobacterfreundii [1]. Such emergence of resistance
has been well documented with most of the enzyme-
stable 13-lactam compounds. Investigators, however,
have ignored whether the rate of resistance varies ac-
cording to the compound considered.
In our laboratory, we have developed a murine
model to detect and quantify the resistance that
emergesduring short-term therapy [2].Wefound that
ceftriaxone was prone to select resistance in En-
terobacter cloacae infection. Using the same model,
wecompared the resistance-producing ability of four
13-lactam antibiotics with distinct antibacterial ac-
tivities. Besides ceftriaxone, which is a third-
generation cephalosporin, we tested the following:
carumonam, a monobactam with a narrower an-
tibacterial spectrum and a more-potent activity
against gram-negative rods [3]; BMY 28142,a newer
cephalosporin with exceptionally low MICs for En-
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terobacteriaceae [4] and low affinity for 13-lactamase
[5]; and Sch 34343, a new penem [6].
Materials and Methods
Chemicals. Antibiotic solutions were prepared
in 0.1 M phosphate buffer from the following diag-
nostic powders of known potency: ceftriaxone and
carumonam (Hoffman La Roche, Basel, Switzer-
land), BMY 28142 (Bristol-Myers AG, Cham, Swit-
zerland), Sch 34343 (Schering Corp., Bloomfield,
NJ), and nitrocefin (Becton-Dickinson AG, Basel,
Switzerland).
Bacterial strains. We used four clinical isolates
ofE. cloacae. Strains 218and 219 were isolated from
CSF in patients with meningitis, and strain 895 from
a patient with postoperative mediastinitis. Strain 908
was provided by R. Then and P. Angehrn [7]. In spite
of their initial susceptibility to the drug administered,
strains 218,219, and 895 were responsible for a ther-
apeutic failure during therapy with a third-generation
cephalosporin. Strains were maintained in skim milk
at - 70 C. When required, the strains were thawed
and grown overnight at 37 C in L-broth (10 g of
Bacto-tryptone, 10 g of NaCI, and 5 g of yeast ex-
tract/liter).
Susceptibility testing. MICs were determined by
an agar-dilution method [8]. The inoculum, 104-105
cfu per spot, was deposited onto Mueller-Hinton
agar with a multiple inoculum replicator. Bacterial
populations were also analyzed on freshly prepared
antibiotic-gradient agar as previously described [9].
Gradients were prepared in 9 x 9-cm petri dishes
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and provided antibiotic concentrations ranging from
zero to the chosen maximum (6.4, 64, or 640 ug/rnl)
as a linear function of the distance from the side of
the dish where the gradients started. One hundred
microliters of an overnight culture (i,e., 2-3 X 108
cfu) was plated onto each gradient. After 18 hr of
incubation at 37 C, bacterial growth was examined,
and when possible, colonies were counted.
f3-Lactamasestudies. Single colonies were grown
overnight in antibiotic-free L-broth. A portion (50
tJI)of this culture was mixed with 10 tJI of a 1 mM
nitrocefin solution. The test was considered positive
if the mixture turned red within 10min. Under these
conditions, a positive reaction occurred only in
strains producing great amounts of ~-lactamase.To
assess the inducibility of a strain with a negative reac-
tion, we performed the nitrocefin test on bacteria
grown in L-broth for 3 hr at 37 C with or without
cefoxitin at a final concentration of 10 ug/ml.
Animal model. We used Swiss ICR mice of both
sexes with a mean weight of 25 g (Institut fiir
Zuchthygiene, Zurich, Switzerland). Experimental
peritonitis was established by an ip injection of 1 ml
of a mixture containing 0.5 ml of a bacterial sus-
pension (0.5-3 x 108 cfu) and 0.5 ml of sterile tal-
cum (125 mg). Talcum was added to avoid sponta-
neous cure of the infection. Antibiotics were
administered sc 2 hr and eventually 8 hr after chal-
lenge: ceftriaxone (one or two doses); carumonam,
BMY 28142, and Sch 34343 (two doses). Twenty-four
hours after inoculation, animals were killed by hyper-
anesthesia. Peritoneal fluid was collected for bac-
terial counts and bacterial population analysis. For
the latter, the fluid was grown overnight at 37 C in
L-broth, and 100 tJI of this culture was plated onto
L-agar containing a gradient of the antibiotic used
for treatment.
Antibiotic assays in mice. Mice were injected ip
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with 1 ml of 0.9070 NaCI, containing 250 mg of ster-
ile talcum. Two hours later, antibiotics were ad-
ministered sc. Then, at different times, mice were
killed (four animals per time interval), and 10 tJIof
peritoneal exudate was sampled and deposited on
6.5-mm paper disks. Assays wereperformed by using
a disk-diffusion method, with Mueller-Hinton agar
and E. coli or Staphylococcus aureus as the test or-
ganism. Apparent half-lives were estimated from
results obtained at three different time intervals.
Results
Bacteriologic studies on initial strains. Before
therapy, all strains of E. cloacae were susceptible to
the four antibiotics tested (table 1). On the gradients,
at the lowest antibiotic concentrations, the bacterial
growth was confluent and sharply limited by a clear-
cut boundary. The antibiotic concentration corre-
sponding to the boundary was similar to the MIC
determined by using the agar-dilution method. At
higher antibiotic concentrations, single colonies were
seen on the gradients prepared with ceftriaxone,
carumonam, and BMY 28142, but not on those pre-
pared with Sch 34343. These colonies wereresistant
clones that were included within the susceptible bac-
terial population. With all strains, the frequency of
the clones was rvl0-6-10-7 • The MIC for the resis-
tant clones varied with the strain and the compound
considered: 25-200 ug/ml with ceftriaxone, 3-20
ug/ml with carumonam, and 0.5-2 ug/ml with BMY
28142 (table 1).When resistant colonies from the gra-
dient were retested by using the agar-dilution
method, their MICs were similar to the minimal con-
centration inhibiting their growth on the gradient
plate. The nitrocefin test applied to bacterial colo-
nies sampled from the confluent growth zone on
Table 1. Susceptibility testing using the agar-dilution method or antibiotic-gradient agar.
MIC (ug/rnl) with agar-dilution method
Minimal concentrations (ug/rnl) inhibiting
the growth of the resistant clones"
Strain no. Ceftriaxone Carumonam BMY 28142 Sch 34343 Ceftriaxone Carumonam BMY 28142 Sch 34343t
218 0.25 0.06 0.03 25 3 0.5
908 0.25 0.06 0.03 30 3 0.5
219 0.25 0.06 0.03 150 10 2
895 0.25 0.06 0.03 200 20 2
• On antibiotic-gradient agar.
t No resistant colonies were seen on gradients prepared with Sch 34343.
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Table 2. Bacterial population analysis from treated mice.
Mice
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No. with acquired resistance (range Mean (range) of loglo cfu
Antibiotic Dose Strains Total treated of fold increase of MIC)· decrease in peritoneal fluid"
Ceftriaxone 50 x 1 218 5 5(40-140) 1.96 (1.15-3.05)
908 5 2 (200) 3.74 (2.0-5.05)
219 5 5 (400-800) 1.64 (1.0-3.0)
895 8 8 (800-1,200) 0.98 (0.0-2.0)
Ceftriaxone 50 x 2 Total 22 22 (140-1,200)
Ceftriaxone 500 x 1 218 5 0- 4.15 (4.05-4.3)
908 5 1 (120) 4.74 (3.3-5.3)
219 5 3 (800) 4.66 (3.9-5.4)
895 5 3 (800) 4.49 (4.0-4.9)
Carumonam 25 x 2 218 6 0- 5.1 (3.5-6.05)
908 6 0- 5.96 (5.3-6.9)
219 6 4 (200) 4.37 (3.0-5.3)
895 6 1 (400) 4.82 (4.2-5.3)
BMY 28142 25 x 2 Total 19 0- 5.80 (3.9-6.7)
Sch 34343 25 x 2 Total 20 0- 2.52 (0.5-5.3)
• Compared with untreated animals. The MIC was defined as the concentration on the gradient corresponding to the boundary
limiting the confluent growth zone. This concentration was similar to the MIC determined by the agar-dilution method.
antibiotic-gradient agar was negative without induc-
tion, but in all cases became immediately positive
after induction by cefoxitin. When the nitrocefin test
was applied to the resistant clones, it was positive
without induction in 40 of 40 colonies from ceftri-
axone gradients, in 20 of 20 colonies from carumo-
nam gradients, and in 18 of 20 colonies from BMY
28142 gradients. The nitrocefin test involved over-
night growth in the L-broth before testing. This pro-
cedure should eliminate any possible induction ef-
fect of the antibiotic-containing gradient plates.
Control mice. Fifty-five infected but untreated
mice were used as controls. Twenty-four hours after
challenge, control animals were killed, and autopsy
showed a peritonitis in all cases with rv1 ml of peri-
toneal exudate. Bacterial counts from this fluid aver-
aged 3.23 x 1010 cfu/ml (range, 5.7 x 109-1.03 x
1011), with no significant differences between the four
strains tested. Because we injected 0.5 to 3 x 108 cfu
into the peritoneal cavity, this meant that an actual
infection occurred regularly. Both MICs and growth
patterns on antibiotic-gradient agars were similar to
those of the initial strains.
Treated mice. A total of 128 mice were infected
and treated. In all cases but one, the number of
colony-forming units per milliliter of peritoneal fluid
was smaller by 0.50 to 6.90 logarithm units in treated
animals than in control, untreated animals, a result
indicating that the treatment had antibacterial ac-
tivity (table 2). Results were analyzed by using Stu-
dent's t test, and the following trends were observed.
BMY 28142 (25 mg/kg, two doses) was the most-
effective therapy, followed by carumonam (25 mg/kg,
two doses; P< .01), and then by ceftriaxone (500 mg/
kg, one dose, P< .05 against carumonam), Sch 34343
(50 rug/kg, two doses, P < .05 against ceftriaxone,
500 mg/kg, one dose), and by ceftriaxone (50 mg/kg,
one dose; an insignificant difference compared with
Sch 34343, P < .001 against ceftriaxone, 500 mg/kg,
one dose).
No resistance occurred after BMY 28142 and Sch
34343 therapies (table 2). In contrast, resistance
emerged after ceftriaxone and carumonam therapies.
The percentages of animals in which resistance was
observed were as follows: 100070 after ceftriaxone (50
mg/kg, two doses); 87070 after ceftriaxone (50 mg/kg,
one dose); 35070 after ceftriaxone (500 mg/kg, one
dose); and 21070 after carumonam. These results were
analyzed by using the 'X: test with the Yates' correc-
tion test, and the following trends were observed.
Ceftriaxone (500 mg/kg, one dose) reduced the risk
of resistance occurring after ceftriaxone (50 rug/kg,
one dose; P < .001); carumonam yielded less resis-
tance than did ceftriaxone (50 mg/ kg, one dose; P
< .(01) and a resistance rate similar to that observed
with ceftriaxone (500 mg/kg, one dose; an insignifi-
cant difference). The absence of resistance after ther-
apy with BMY 28142 and Sch 34343 was a result
different from that obtained with ceftriaxone (P
< .001 or P < .05 depending on the dose given to
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* ND = not determined.
t Concentration determined after 45 min.
the mice), but a result similar to that obtained with
carumonam (an insignificant difference).
The shift towards resistance was always important,
but generally, greater increases in MICs were ob-
served with strains 219and 895 than with strains 908
and 218 (table 2).
Antibiotic assays. Results from 60 mice (table
3) showed that 60 min after dosing, concentrations
of ceftriaxone, carumonam, BMY 28142, or Sch
34343 in the peritoneal fluid exceeded the MIC for
the four strains tested (table 1) but not necessarily
the MICs for the resistant clones (table 1). Appar-
ent half-lives of the four 13-lactam compounds in the
peritoneal fluid suggested that 22 hr and 16hr after
dosing, when the mice were killed, the residual an-
tibiotic concentrations in the peritoneal fluid were
too low for interfering with the bacterial population
analysis.
Discussion
In our animal model, bacterial resistance emerged
rapidly after therapy with carumonam and ceftri-
axone. For instance, with ceftriaxone, resistance rates
in the mouse were 870/0 after the first injection of
50 mg/kg and 1000/0 after the second injection. A
major finding of this study was that the rate of re-
sistance emerging in vivo varied according to the
compound administered. Heterogeneous susceptibil-
ity to 13-lactam compounds among the cells within
an Enterobacter population, a phenomenon already
described a decade ago [10],probably accounted for
these differences. Thus, the gradients prepared with
carumonam or ceftriaxone and plated with Entero-
bacter before therapeutic exposure showed clones
growing far over the MIC level. These preexisting
resistant clones were probably selected by the treat-
ment and preferentially developed. In contrast, no
resistant colonies grew on gradients prepared with
Sch 34343, which, in turn, selected no resistance in
the animals. BMY 28142, which allowed resistant
clones to grow on the gradients but yielded no emer-
gence of resistance in our model, seemed to be an
exception. In fact, the levelof resistance of the preex-
isting clones together with the pharmacokinetic data
must be considered. In the case of BMY 28142, the
resistant colonies were inhibited by 0.5-2IJ.g/ml (ta-
ble 1) when the mean concentration of the drug in
the peritonealfluid, 60min after dosing, was f\JI0times
higher than these inhibitory concentrations (table 3).
This "therapeutic index" (i.e., antibiotic concentra-
tions in the peritoneal fluid over the level of resis-
tance of the clones) was regularly lower with ceftri-
axone and carumonam than with BMY 28142.Also,
the lower dose of ceftriaxone (50 mg/kg) produced
lower concentrations in the peritoneal fluid, i.e.,
smaller therapeutic index and accordingly selected
resistance more frequently than did the higher dose
(500 mg/kg). Moreover, in the latter case, as after
carumonam therapy, resistance emerged almost ex-
clusively in strains 219and 895, which contained the
most-resistant clones.
Thus, for a given J3-lactam compound, the resis-
tant clones, together with the pharmacokinetic data,
could be associated with the further emergence of
resistance in the mouse treated with this antibiotic.
On the contrary, the number ofcolonies growing over
the boundary on a gradient was a poor predictor be-
cause ceftriaxone, carumonam, and BMY 28142
yielded a similar number of resistant clones on the
gradient before therapy, but different resistance rates
after therapy. The frequency of these resistant clones
was f\JI0-6-10-7; this frequency was similar to that
observed in other studies [10, 11]. It has been stressed
[12] that the resistant clones are often overlooked by
the conventional susceptibility tests that use an in-
oculum of only 104-105 cfu, a procedure causing
"very major" errors. A comparison of the two pan-
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els of table 1 gives an illustration of such discrepan-
cies. Indeed, population analysis on antibiotic-
gradient agar, using an inoculum of lOS cfu, provided
a better prediction of further emergence of resistance
than did the usual MIC determination by agar-
dilution.
The nitrocefin test applied to the resistant clones
was almost always positive (wefound only two nega-
tive colonies from the BMY 28142 gradient) after
subculture in antibiotic-free medium. This finding
indicated that most of the resistant clones produced
constitutively great amounts of B-Iactamase.
The most-convincing evidence that B-Iactamase is
associated with the resistance is the transfer of the
chromosomal gene from a stably derepressed mu-
tant of E. cloacae to Escherichia coli; this transfer
leads to acquisition of B-Iactam resistance by the re-
cipient E. coli [13]. In our study, however, the nitrofe-
cin test showed that our initial strains were induc-
ible by cefoxitin. In vivo, induction of B-Iactamase
may have an additional advantage over the consti-
tutive production of the enzyme- the higher induced
levels might allow neutralization of more B-Iactam
molecules.
Extrapolating the results from our experimental
studies directly to the clinical situation would be
speculative. In this study, we put the antibiotics to
a very severe test by using a high bacterial inoculum
and talcum, which acted as a foreign body. Such un-
favorable conditions are not commonly encountered
in the clinical setting. Nevertheless, some of our ob-
servations might be helpful for the clinician. Emer-
gence of resistance after therapy with the newer B-
lactam antibiotics was dose related, and the ability
to produce resistance varied according to the B-
lactam compound considered. This supports the idea
of avoiding underdosing patients, especially at ini-
tiation of therapy, when the bacterial populations
are high. Also, one may hope that drugs such as Sch
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34343 or BMY 28142 will limit the risk of selecting
resistance during therapy of E. cloacae infections.
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